Tokyo Tape
Sign in
← Medinet

Annual report

2370.TEDINET S100UX6K
Period2023-10-01 → 2024-09-30
Filed2024-12-18
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
MetricValuePeriodScopeSource row
Revenue¥769m2023-10-01 → 2024-09-30StandaloneNet sales
Revenue¥662m2022-10-01 → 2023-09-30StandaloneNet sales
Revenue¥634m2021-10-01 → 2022-09-30dStandaloneNet sales (5-year summary)
Revenue¥683m2020-10-01 → 2021-09-30dStandaloneNet sales (5-year summary)
Revenue¥783m2019-10-01 → 2020-09-30dStandaloneNet sales (5-year summary)
Operating income−¥1.4bn2023-10-01 → 2024-09-30StandaloneOperating income
Operating income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOperating income
Ordinary income−¥1.3bn2023-10-01 → 2024-09-30StandaloneOrdinary income
Ordinary income−¥1.4bn2022-10-01 → 2023-09-30StandaloneOrdinary income
Ordinary income−¥1.3bn2021-10-01 → 2022-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥871m2020-10-01 → 2021-09-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥837m2019-10-01 → 2020-09-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.3bn2023-10-01 → 2024-09-30StandaloneIncome before income taxes
Profit before tax−¥1.4bn2022-10-01 → 2023-09-30StandaloneIncome before income taxes
Net income−¥1.3bn2023-10-01 → 2024-09-30StandaloneProfit loss
Net income−¥1.4bn2022-10-01 → 2023-09-30StandaloneProfit loss
Net income−¥1.3bn2021-10-01 → 2022-09-30dStandaloneNet income loss (5-year summary)
Net income−¥843m2020-10-01 → 2021-09-30dStandaloneNet income loss (5-year summary)
Net income−¥842m2019-10-01 → 2020-09-30dStandaloneNet income loss (5-year summary)
Total assets¥5.7bnat 2024-09-30StandaloneAssets
Total assets¥5.6bnat 2023-09-30StandaloneAssets
Total assets¥6.1bnat 2022-09-30dStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2021-09-30dStandaloneTotal assets (5-year summary)
Total assets¥5.2bnat 2020-09-30dStandaloneTotal assets (5-year summary)
Total liabilities¥509mat 2024-09-30StandaloneLiabilities
Total liabilities¥590mat 2023-09-30StandaloneLiabilities
Net assets / equity¥5.2bnat 2024-09-30StandaloneNet assets
Net assets / equity¥5.0bnat 2023-09-30StandaloneNet assets
Net assets / equity¥5.5bnat 2022-09-30dStandaloneNet assets
Net assets / equity¥4.9bnat 2021-09-30dStandaloneNet assets (5-year summary)
Net assets / equity¥4.8bnat 2020-09-30dStandaloneNet assets (5-year summary)
Cash and deposits¥4.7bnat 2024-09-30StandaloneCash and deposits
Cash and deposits¥4.4bnat 2023-09-30StandaloneCash and deposits
Cash & equivalents¥4.7bnat 2024-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.4bnat 2023-09-30StandaloneCash and cash equivalents
Cash & equivalents¥4.5bnat 2022-09-30dStandaloneCash and cash equivalents
Cash & equivalents¥4.1bnat 2021-09-30dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.6bnat 2020-09-30dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.3bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.3bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.2bn2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥975m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥633m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥65m2023-10-01 → 2024-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow¥3m2022-10-01 → 2023-09-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥20m2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥344m2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥86m2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2023-10-01 → 2024-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.2bn2022-10-01 → 2023-09-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥1.6bn2021-10-01 → 2022-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2020-10-01 → 2021-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.8bn2019-10-01 → 2020-09-30dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-5.042023-10-01 → 2024-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.652022-10-01 → 2023-09-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.332021-10-01 → 2022-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-4.882020-10-01 → 2021-09-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.192019-10-01 → 2020-09-30dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥19.62at 2024-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥21.64at 2023-09-30StandaloneNet assets per share (5-year summary)
Net assets per share¥26.03at 2022-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥27.31at 2021-09-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥29.6at 2020-09-30dStandaloneNet assets per share (5-year summary)
Equity ratio91.1%at 2024-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2023-09-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2022-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.8%at 2021-09-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio90.7%at 2020-09-30dStandaloneEquity to asset ratio (5-year summary)
ROE-25.0%2023-10-01 → 2024-09-30StandaloneRate of return on equity (5-year summary)
ROE-27.3%2022-10-01 → 2023-09-30StandaloneRate of return on equity (5-year summary)
ROE-24.1%2021-10-01 → 2022-09-30dStandaloneRate of return on equity (5-year summary)
ROE-17.5%2020-10-01 → 2021-09-30dStandaloneRate of return on equity (5-year summary)
ROE-23.0%2019-10-01 → 2020-09-30dStandaloneRate of return on equity (5-year summary)
Shares issued264,515,306at 2024-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued232,160,757at 2023-09-30StandaloneTotal number of issued shares (5-year summary)
Shares issued211,730,423at 2022-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued178,750,423at 2021-09-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued160,830,423at 2020-09-30dStandaloneTotal number of issued shares (5-year summary)
Employees112at 2024-09-30StandaloneNumber of employees
Employees98at 2023-09-30StandaloneNumber of employees
Employees96at 2022-09-30dStandaloneNumber of employees
Employees83at 2021-09-30dStandaloneNumber of employees
Employees78at 2020-09-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 46
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-10-01 → 2024-09-30¥2m
Reconciling Itemsreconcilingdepreciation2023-10-01 → 2024-09-30¥18m
Reconciling Itemsreconcilingsegment assetsat 2024-09-30¥4.9bn
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2024-09-30−¥577m
Cellular And Tissue Based Product Businessreportable segmentcapex2023-10-01 → 2024-09-30¥21m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥36m
Cellular And Tissue Based Product Businessreportable segmentemployeesat 2024-09-3018 pure
Cellular And Tissue Based Product Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥245,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2024-09-30¥116m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥435m
Contracted Cell Manufacturing Businessreportable segmentcapex2023-10-01 → 2024-09-30¥23m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2023-10-01 → 2024-09-30¥61m
Contracted Cell Manufacturing Businessreportable segmentemployeesat 2024-09-3078 pure
Contracted Cell Manufacturing Businessreportable segmentrevenue2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2023-10-01 → 2024-09-30¥768m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2024-09-30¥667m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2023-10-01 → 2024-09-30−¥374m
—segment totalcapex2023-10-01 → 2024-09-30¥44m
—segment totaldepreciation2023-10-01 → 2024-09-30¥97m
—segment totalrevenue2023-10-01 → 2024-09-30¥769m
—segment totalrevenue external2023-10-01 → 2024-09-30¥769m
—segment totalsegment assetsat 2024-09-30¥783m
—segment totalsegment profit2023-10-01 → 2024-09-30−¥808m
Reconciling Itemsreconcilingcapex2022-10-01 → 2023-09-30¥6m
Reconciling Itemsreconcilingdepreciation2022-10-01 → 2023-09-30¥19m
Reconciling Itemsreconcilingsegment assetsat 2023-09-30¥4.8bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2023-09-30−¥583m
Cellular And Tissue Based Product Businessreportable segmentcapex2022-10-01 → 2023-09-30¥25m
Cellular And Tissue Based Product Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥28m
Cellular And Tissue Based Product Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥467,000
Cellular And Tissue Based Product Businessreportable segmentsegment assetsat 2023-09-30¥169m
Cellular And Tissue Based Product Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥496m
Contracted Cell Manufacturing Businessreportable segmentcapex2022-10-01 → 2023-09-30¥30m
Contracted Cell Manufacturing Businessreportable segmentdepreciation2022-10-01 → 2023-09-30¥55m
Contracted Cell Manufacturing Businessreportable segmentrevenue2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentrevenue external2022-10-01 → 2023-09-30¥661m
Contracted Cell Manufacturing Businessreportable segmentsegment assetsat 2023-09-30¥668m
Contracted Cell Manufacturing Businessreportable segmentsegment profit2022-10-01 → 2023-09-30−¥346m
—segment totalcapex2022-10-01 → 2023-09-30¥55m
—segment totaldepreciation2022-10-01 → 2023-09-30¥84m
—segment totalrevenue2022-10-01 → 2023-09-30¥662m
—segment totalrevenue external2022-10-01 → 2023-09-30¥662m
—segment totalsegment assetsat 2023-09-30¥837m
—segment totalsegment profit2022-10-01 → 2023-09-30−¥842m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 982
ItemContextValueUnit
Accounts receivable tradeCurrentYearInstant_NonConsolidatedMember227801000JPY
Accumulated depreciation ppe by groupPrior1YearInstant_NonConsolidatedMember-1368938000JPY
Accumulated depreciation ppe by groupCurrentYearInstant_NonConsolidatedMember-1460512000JPY
Revenue from contracts with customersPrior1YearDuration_NonConsolidatedMember661543000JPY
Revenue from contracts with customersCurrentYearDuration_NonConsolidatedMember768501000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember228884000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember250892000JPY
Provision for bonuses sgaPrior1YearDuration_NonConsolidatedMember28354000JPY
Provision for bonuses sgaCurrentYearDuration_NonConsolidatedMember30624000JPY
Provision for share based payments sgaPrior1YearDuration_NonConsolidatedMember8027000JPY
Provision for share based payments sgaCurrentYearDuration_NonConsolidatedMember11141000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember33045000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember30023000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember496674000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember452775000JPY
Commission fee sgaPrior1YearDuration_NonConsolidatedMember234345000JPY
Commission fee sgaCurrentYearDuration_NonConsolidatedMember212233000JPY
Provision of allowance for doubtful accounts sgaPrior1YearDuration_NonConsolidatedMember3755000JPY
Provision of allowance for doubtful accounts sgaCurrentYearDuration_NonConsolidatedMember-828000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember496674000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember452775000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember661075000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember467000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember661543000JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YearDuration_NonConsolidatedMember661543000JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YearDuration_NonConsolidatedMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember661075000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember467000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember661543000JPY
Net salesPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember－JPY
Net salesPrior1YearDuration_NonConsolidatedMember661543000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember-346124000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember-496361000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember-842485000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember-583466000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-1425952000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember667579000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember169163000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_ReportableSegmentsMember836742000JPY
AssetsPrior1YearInstant_NonConsolidatedMember_ReconcilingItemsMember4797402000JPY
AssetsPrior1YearInstant_NonConsolidatedMember5634145000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember55356000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember28357000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReportableSegmentsMember83713000JPY
Depreciation segment informationPrior1YearDuration_NonConsolidatedMember_ReconcilingItemsMember19456000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-09-30pass rounding
balance sheet identitynon_consolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-09-30pass
statement vs summary · net assetsnon_consolidated 2023-09-30pass
statement vs summary · net assetsnon_consolidated 2024-09-30pass
statement vs summary · operating cash flownon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · operating cash flownon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · revenuenon_consolidated 2022-10-01/2023-09-30pass
statement vs summary · revenuenon_consolidated 2023-10-01/2024-09-30pass
statement vs summary · total assetsnon_consolidated 2023-09-30pass
statement vs summary · total assetsnon_consolidated 2024-09-30pass